Urological Oncology and Cancer Surveillance
Urological oncology is the branch of urology concerned with cancers of the genitourinary tract, including the kidney, renal pelvis and ureter, bladder, prostate, testis, and penis. It spans the epidemiology, classification, diagnosis, and follow-up surveillance of these malignancies, which together account for a substantial share of the global cancer burden, and it sits at the interface of surgery, medical oncology, radiology, and pathology.
Definition
Urological oncology is the study and clinical management of neoplasms arising in the urinary tract and male genital organs (urogenital neoplasms), encompassing their epidemiology, histopathological classification, staging, and surveillance.
Scope
This area orients the reader to the major genitourinary cancers as a family and links to detailed topic entries for each. It covers how these tumours are grouped and named under the WHO and TNM classifications, the broad descriptive epidemiology that distinguishes them, and the concept of structured post-treatment surveillance. It is a reference-educational overview, not a source of diagnostic or treatment recommendations.
Sub-topics
Core questions
- Which organs and tumour types make up the genitourinary cancers, and how are they classified?
- How do the major urological cancers differ in incidence, risk factors, and natural history?
- What principles underlie staging and grading of these tumours?
- What is the rationale for structured surveillance after treatment of a genitourinary cancer?
Key concepts
- Genitourinary (urogenital) neoplasms
- WHO classification of urinary and male genital tumours
- TNM staging and tumour grade
- Descriptive epidemiology (incidence and mortality)
- Cancer surveillance and follow-up
- Histopathological subtyping
- Risk stratification
Clinical relevance
The genitourinary cancers are among the most common malignancies worldwide, with prostate, bladder, and kidney cancers contributing a large share of new diagnoses each year (Bray, 2024). Understanding how these tumours are classified and staged underpins the interpretation of cancer statistics, pathology reports, and the surveillance schedules used after treatment. This overview describes how the field is organised and is not a basis for individual diagnostic or treatment decisions.
Epidemiology
Genitourinary cancers collectively represent a major component of cancer incidence and mortality. In global estimates for 2022, prostate cancer was among the leading cancers in men, while bladder and kidney cancers also ranked among the more common malignancies, with marked variation by sex, age, geography, and access to screening or diagnostic services (Bray, 2024). Testicular and penile cancers are comparatively rare but are important because of the young age at onset (testicular) and the morbidity and preventable risk factors involved (penile).
Evidence & guidelines
Tumour classification in this area follows the World Health Organization classification of tumours of the urinary system and male genital organs, with the prostate and bladder covered in one part and renal, penile, and testicular tumours in another (Moch, 2016; Humphrey, 2016). Staging follows the TNM system, and professional bodies such as the European Association of Urology and the American Urological Association publish disease-specific guidelines; clinicians should consult the current versions of these documents.
Related topics
Seminal works
- bray-2024
- moch-2016
- humphrey-2016
Frequently asked questions
- Which cancers are included in urological oncology?
- Cancers of the kidney, renal pelvis and ureter, urinary bladder, prostate, testis, and penis (and scrotum), collectively termed genitourinary or urogenital neoplasms.
- What does cancer surveillance mean in this context?
- It refers to the structured schedule of clinical, laboratory, and imaging follow-up used after a genitourinary cancer is treated, intended to detect recurrence or progression; the specific schedules are defined by disease-specific guidelines.